Forest Laboratories (FRX)
Create an AlertFRX Key Stats
| Income Statement | |
| Revenue TTM | 3.126B |
| Revenue Quarterly YoY Growth | -22.17% |
| EPS Diluted TTM | -0.12 |
| EPS Diluted Quarterly YoY Growth | -76.31% |
| Net Income TTM | -32.10M |
| Profitability | |
| Gross Profit Margin Quarterly | 78.36% |
| Profit Margin Quarterly | 5.53% |
| Dividend | |
| Dividend Yield | 0% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 11.15B |
| Enterprise Value | 9.358B |
| PE Ratio TTM | |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | 1.968 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 0.00 |
| Free Cash Flow | -39.14M |
| Return on Equity | 2.03% |
FRX News
- Forest Laboratories Inc. (FRX) to Bid for Elan (ELN) Street Insider Jun 19
- Forest Rises On Unusually High Volume (FRX) Jun 19
- Almirall CEO Eyes $11.6 Billion COPD Market Smokers Fuel Jun 18
- 5 High Growth Healthcare Stocks With Heavy Insider Buying Jun 18
- US Launch of Forest's Namenda XR Jun 17
- Synergy Pharma rises as analyst starts coverage Jun 17
- Can Cempra Beat The Superbugs? Jun 17
- US Launch of Forest's Namenda XR - Analyst Blog Zacks Jun 17
- Forest Reaches New 52-Week High (FRX) Jun 17
- Forest Laboratories Inc. (FRX): Today's Featured Health Care Winner Jun 14
FRX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Forest Laboratories is up 20.56% over the last year vs S&P 500 Total Return up 23.89%, Allergan up 6.85%, and Alexza Pharmaceuticals up 77.04%.
FRX Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these FRX related companies
Pro Ratings for FRX
Pro Report PDF for FRX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download FRX Pro Report PDF
Pro Strategies Featuring FRX
Did Forest Laboratories make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
FRX Profile
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Forest Laboratories, Inc. is a US based pharmaceutical company, engaged in identifying, developing, manufacturing and marketing of pharmaceutical products including ethical and over the counter drugs in branded and generic forms. Forest has franchises in the areas of cardiovascular and central nervous systems. The company is present in therapeutic areas including cardiovascular, central nervous system, endocrinology, pain management, and respiratory. As of 2007, approached almost a billion US dollars a year, which put it on the list of the top 100 global corporations in R&D spending. Forest Laboratories is also known for licensing European pharmaceuticals for sale in the United States. The company operates in the US, Ireland, Netherlands and the UK through its subsidiaries. Forest Laboratories is headquartered in New York, the US.
Other FRX Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| FRX | 41.84 | +0.28 | +0.66% | 11.15B |
